RegeneRx Thymosin beta 4 stimulates maturation of central nervous system progenitor cells

RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") has announced that researchers have found that Thymosin beta 4 (Tβ4), in a dose dependent manner, stimulates oligodendrogenesis, the process by which central nervous system (CNS) progenitor cells (immature specialized brain cells) become oligodendrocytes that secrete myelin, the covering of nerve fibers. This process is important for the repair, regeneration and function of CNS tissue damaged by disease or trauma.

The research team was led by Dr. Dan Morris, of the Henry Ford Hospital System in Detroit, Michigan. Dr. Morris is presenting his findings at the Society of Academic Emergency Medicine meeting on June 1st.

Dr. Morris has previously shown that Tβ4 significantly improves neurological functional outcome in a CNS rat model after embolic stroke. His work in the field brings us closer to understanding the mechanisms underlying the differentiation of immature oligodendrocytes into mature oligodendrocytes in patients suffering stroke, multiple sclerosis and traumatic brain injury.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The new science behind the health benefits of caffeine